Language: English
Published by LAP Lambert Academic Publishing, 2009
ISBN 10: 3838309707 ISBN 13: 9783838309705
Seller: Ria Christie Collections, Uxbridge, United Kingdom
£ 39.71
Quantity: Over 20 available
Add to basketCondition: New. In.
Language: English
Published by LAP Lambert Academic Publishing 2009-08-26, 2009
ISBN 10: 3838309707 ISBN 13: 9783838309705
Seller: Chiron Media, Wallingford, United Kingdom
Paperback. Condition: New.
Language: English
Published by LAP LAMBERT Academic Publishing, 2010
ISBN 10: 3838309707 ISBN 13: 9783838309705
Seller: preigu, Osnabrück, Germany
Taschenbuch. Condition: Neu. Physiologically Based Pharmacokinetic Modeling | Of Monoclonal Antibodies | Jasmine Davda | Taschenbuch | 112 S. | Englisch | 2010 | LAP LAMBERT Academic Publishing | EAN 9783838309705 | Verantwortliche Person für die EU: OmniScriptum GmbH & Co. KG, Bahnhofstr. 28, 66111 Saarbrücken, info[at]akademikerverlag[dot]de | Anbieter: preigu.
Language: English
Published by LAP Lambert Academic Publishing, 2009
ISBN 10: 3838309707 ISBN 13: 9783838309705
Seller: PBShop.store US, Wood Dale, IL, U.S.A.
PAP. Condition: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Language: English
Published by LAP Lambert Academic Publishing, 2009
ISBN 10: 3838309707 ISBN 13: 9783838309705
Seller: PBShop.store UK, Fairford, GLOS, United Kingdom
£ 40.85
Quantity: Over 20 available
Add to basketPAP. Condition: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Language: English
Published by LAP LAMBERT Academic Publishing Mai 2010, 2010
ISBN 10: 3838309707 ISBN 13: 9783838309705
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book describes the application of physiologically based pharmacokinetic (PBPK) modeling to characterize the disposition of therapeutic monoclonal antibodies (MAbs). These macromolecules exhibit distinctly different pharmacokinetic features compared with conventional small-molecule drugs. A PBPK model was developed to characterize the biodistribution of the pancarcinoma MAb CC49 in normal and neoplastic tissues of nude mice. The model included all the major processes involved in determining the disposition characteristics of MAbs. The applicability of the model was tested by predicting the disposition of di- and tetravalent scFv constructs of CC49 in mice. Further, the model was applied to study the differences in disposition between Mabs labeled with 125I and 177Lu. Finally, the clinical utility of the model was tested by attempting to predict the disposition and tumor uptake of CC49 in patients. This model may be used to study the biodistribution and tumor localization of different combinations of radionuclides and engineered antibody fragments in an effort to establish the most effective approach to achieve the optimal therapeutic ratio for tumor therapy. 112 pp. Englisch.
Language: English
Published by LAP LAMBERT Academic Publishing, 2010
ISBN 10: 3838309707 ISBN 13: 9783838309705
Seller: moluna, Greven, Germany
Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Davda JasmineJasmine Davda received her MS and Ph.D. in Pharmaceutical Sciences from the University of Nebraska in 2000 and 2007, respectively. Between 2001 and 2004, Dr. Davda was Research Scientist at Piramal Life Sciences, Indi.
Language: English
Published by LAP LAMBERT Academic Publishing Mai 2010, 2010
ISBN 10: 3838309707 ISBN 13: 9783838309705
Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germany
Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This book describes the application of physiologically based pharmacokinetic (PBPK) modeling to characterize the disposition of therapeutic monoclonal antibodies (MAbs). These macromolecules exhibit distinctly different pharmacokinetic features compared with conventional small-molecule drugs. A PBPK model was developed to characterize the biodistribution of the pancarcinoma MAb CC49 in normal and neoplastic tissues of nude mice. The model included all the major processes involved in determining the disposition characteristics of MAbs. The applicability of the model was tested by predicting the disposition of di- and tetravalent scFv constructs of CC49 in mice. Further, the model was applied to study the differences in disposition between Mabs labeled with 125I and 177Lu. Finally, the clinical utility of the model was tested by attempting to predict the disposition and tumor uptake of CC49 in patients. This model may be used to study the biodistribution and tumor localization of different combinations of radionuclides and engineered antibody fragments in an effort to establish the most effective approach to achieve the optimal therapeutic ratio for tumor therapy.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 112 pp. Englisch.
Language: English
Published by LAP LAMBERT Academic Publishing, 2009
ISBN 10: 3838309707 ISBN 13: 9783838309705
Seller: AHA-BUCH GmbH, Einbeck, Germany
Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - This book describes the application of physiologically based pharmacokinetic (PBPK) modeling to characterize the disposition of therapeutic monoclonal antibodies (MAbs). These macromolecules exhibit distinctly different pharmacokinetic features compared with conventional small-molecule drugs. A PBPK model was developed to characterize the biodistribution of the pancarcinoma MAb CC49 in normal and neoplastic tissues of nude mice. The model included all the major processes involved in determining the disposition characteristics of MAbs. The applicability of the model was tested by predicting the disposition of di- and tetravalent scFv constructs of CC49 in mice. Further, the model was applied to study the differences in disposition between Mabs labeled with 125I and 177Lu. Finally, the clinical utility of the model was tested by attempting to predict the disposition and tumor uptake of CC49 in patients. This model may be used to study the biodistribution and tumor localization of different combinations of radionuclides and engineered antibody fragments in an effort to establish the most effective approach to achieve the optimal therapeutic ratio for tumor therapy.